Skip to content
approvedHormone Regulation

Degarelix

Also known as: Firmagon, Degarelix Acetate

Degarelix is a synthetic GnRH antagonist FDA-approved for the treatment of advanced prostate cancer. Unlike GnRH agonists (leuprolide, goserelin, triptorelin), degarelix directly blocks GnRH receptors without causing an initial testosterone flare, achieving castrate testosterone levels within 1-3 days rather than 2-4 weeks. This rapid suppression is clinically critical for patients with impending spinal cord compression, severe urinary obstruction, or other situations where the testosterone flare from agonists could be dangerous. Administered as a monthly subcutaneous injection, degarelix represents a mechanistically distinct approach to androgen deprivation therapy.

3 cited references·5 researched benefits

Quick Answer

Degarelix (Firmagon) is a GnRH antagonist that directly blocks pituitary GnRH receptors, achieving castrate testosterone levels within 1-3 days without the initial testosterone flare seen with GnRH agonists. FDA-approved for advanced prostate cancer, it is especially valuable for patients at risk of flare complications including spinal cord compression and urinary obstruction. It is given as a monthly subcutaneous injection in the abdominal area.

Key Facts

Mechanism
Degarelix is a synthetic decapeptide that competitively binds to GnRH receptors on pituitary gonadotroph cells, immediately blocking the action of endogenous GnRH without activating the receptor. This is fundamentally different from GnRH agonists, which first activate and then desensitize the receptor. By preventing GnRH signaling, degarelix causes an immediate decline in LH and FSH, followed by rapid testosterone suppression to castrate levels (below 50 ng/dL) typically within 1-3 days. There is no initial surge or flare. After subcutaneous injection, degarelix forms a gel-like depot at the injection site that slowly releases the drug over approximately one month. The depot formation is responsible for injection site reactions but provides sustained receptor blockade.
Research Status
approved
Half-Life
~53 days (depot formulation)
Molecular Formula
C₈₂H₁₀₃ClN₁₈O₁₆
Primary Use
Hormone Regulation
Table of Contents

Benefits

  • No testosterone flare — achieves castrate testosterone within 1-3 days without the dangerous initial hormone surge seen with GnRH agonistsstrong
  • Fastest testosterone suppression of any hormonal therapy — 96% of patients achieve castrate levels within 3 days vs. 2-4 weeks with GnRH agonistsstrong
  • Lower risk of cardiovascular events — post-hoc analyses and observational studies suggest reduced cardiovascular risk compared to GnRH agonistsmoderate
  • No need for antiandrogen flare protection — simplifies treatment initiation and avoids antiandrogen side effectsstrong
  • Superior PSA progression-free survival — pooled analysis of Phase 3 trials showed improved PSA control compared to leuprolide, particularly in patients with high baseline PSAmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous injection (loading dose)240 mg (given as two 120 mg injections)Once (first dose only)Two subcutaneous injections of 120 mg each, administered in different sites on the abdominal wall. This loading dose achieves rapid castrate levels within 1-3 days.
Subcutaneous injection (maintenance)80 mgEvery 28 daysMonthly maintenance dose. Must be administered by healthcare provider due to subcutaneous depot technique. Injection site should be rotated and areas with pressure from belts or waistbands avoided.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Injection site reactions — pain, erythema, swelling, and induration at the subcutaneous injection site; occurs in 35-44% of patients due to depot gel formationcommon
  • Hot flashes — experienced by 25-30% of patients, similar to other forms of androgen deprivation therapycommon
  • Weight gain — reported in 10-15% of patients on long-term androgen deprivationcommon
  • Elevated liver enzymes — transient increases in transaminases reported; liver function monitoring recommendedrare
  • Decreased bone mineral density — progressive bone loss with prolonged androgen deprivation; DEXA monitoring and bone-protective agents recommendedserious
  • Fatigue and decreased libido — expected effects of castrate testosterone levels; reported in 10-20% of patientscommon
  • QT prolongation — rare reports; ECG monitoring may be warranted in patients with pre-existing cardiac conduction abnormalitiesserious

Frequently Asked Questions

Why is degarelix preferred over Lupron in some prostate cancer patients?
Degarelix is preferred in patients where the GnRH agonist testosterone flare could be dangerous — specifically those with impending spinal cord compression, severe urinary obstruction, or high-volume metastatic disease causing bone pain. It is also preferred for patients who need rapid testosterone suppression (e.g., before radiation therapy). Some oncologists prefer degarelix for patients with pre-existing cardiovascular disease based on data suggesting lower cardiovascular event rates compared to GnRH agonists. The main disadvantage is monthly injections with significant injection site reactions.
What is the difference between a GnRH agonist and a GnRH antagonist?
GnRH agonists (leuprolide, goserelin, triptorelin) initially stimulate GnRH receptors, causing a 1-2 week testosterone surge before receptor downregulation leads to suppression. GnRH antagonists (degarelix, abarelix) directly block GnRH receptors without any initial activation, causing immediate hormone suppression with no flare. Both achieve the same endpoint (castrate testosterone), but antagonists get there faster and more safely. Agonists have more convenient long-acting depot formulations (up to 6 months), while degarelix requires monthly injections.
Why does degarelix cause more injection site reactions than other hormonal injections?
Degarelix forms a gel-like depot at the subcutaneous injection site, which is necessary for its sustained-release properties. This depot formation triggers a local inflammatory reaction in approximately 35-44% of patients, manifesting as pain, swelling, redness, and induration that can persist for days to weeks. The reactions are typically mild to moderate and tend to decrease with subsequent injections. Proper injection technique (slow injection, correct needle angle, site rotation) can help minimize reactions. The large loading dose (two 120 mg injections) at initiation tends to cause the most pronounced site reactions.
Can you switch from Lupron to degarelix or vice versa?
Yes. Switching from a GnRH agonist to degarelix is straightforward — degarelix can be started at any point, and the switch may be considered if PSA is rising despite agonist therapy (testosterone escape) or if cardiovascular concerns arise. No washout period is needed. Switching from degarelix to a GnRH agonist is also possible; the agonist can be initiated when the next degarelix dose would be due. Antiandrogen flare protection should be considered when switching to an agonist, though the residual antagonist effect may provide some protection.
Does degarelix preserve bone density better than GnRH agonists?
No. Degarelix and GnRH agonists both achieve castrate testosterone levels, and the bone density loss is related to the testosterone suppression rather than the specific mechanism of suppression. Both classes carry similar risks of osteoporosis and fractures with prolonged use. Bone-protective strategies (calcium, vitamin D, weight-bearing exercise, and bisphosphonates or denosumab in high-risk patients) should be employed regardless of which agent is used for androgen deprivation therapy.

References

  1. 1
    Degarelix: a review of its use in patients with prostate cancer(2008)PubMed ↗
  2. 2
    Degarelix versus leuprolide in prostate cancer: a Phase 3 randomized trial (CS21)(2010)PubMed ↗
  3. 3
    Cardiovascular risk with GnRH agonists and antagonists: a systematic review and meta-analysis(2014)PubMed ↗

Latest Research

Last updated: 2026-02-19